Investing.com - J&J (NYSE:JNJ) reported on Tuesday fourth-quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
J&J announced earnings per share of $2.13 on revenue of $24.8 billion. Analysts polled by Investing.com anticipated EPS of $2.12 on revenue of $25.28 billion.
Overall, fourth-quarter sales grew 10.4%.
The company revealed that Consumer Health worldwide adjusted operational sales increased 3.8%, mainly driven by over-the-counter products including TYLENOL, in addition to NEUTROGENA and AVEENO products. However, the growth was partially impacted by supply constraints.
Furthermore, JNJ's pharmaceutical worldwide adjusted operational sales grew 13.6%, helped by several biologic treatments and its Janssen Covid-19 vaccine.
J&J shares are up 0.8% following the report.